A Phase II Study of Combination Nilotinib and Hyper-CVAD in Patients Newly Diagnosed With Philadelphia-Chromosome Positive Acute Lymphoblastic Leukemia or Chronic Myeloid Leukemia Blast-Phase Lymphoid Lineage

Trial Profile

A Phase II Study of Combination Nilotinib and Hyper-CVAD in Patients Newly Diagnosed With Philadelphia-Chromosome Positive Acute Lymphoblastic Leukemia or Chronic Myeloid Leukemia Blast-Phase Lymphoid Lineage

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 01 Jan 2015

At a glance

  • Drugs Nilotinib (Primary) ; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Folinic acid; Mesna; Methotrexate; Prednisone; Rituximab; Vincristine
  • Indications Acute lymphoblastic leukaemia; Chronic myeloid leukaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 Jan 2015 Status changed from recruiting to active, no longer recruiting as reported by Mayo Clinic record.
    • 05 Mar 2013 Planned End Date changed from 1 Sep 2014 to 1 Sep 2017 as reported by ClinicalTrials.gov record.
    • 24 Dec 2012 New source identified and integrated (Mayo Clinic record, 11-007469).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top